May 29, 2024
Traumatic Brain Injury Therapeutics Market

Brain Injury Therapeutics Driven by Rising Cases of Head Trauma

Traumatic brain injuries occur due to head trauma caused by falls, traffic accidents, sports injuries or violence. It encompasses concussions or other lesions to the brain from external mechanical forces such as rapid acceleration or deceleration, impacts, blasts or projectiles. Traumatic brain injury therapeutics involve drugs and devices used for acute treatment and long term management of patients with moderate to severe traumatic brain injury. Advancement in areas of pharmaceuticals, neurostimulation, neuroprosthetics, stem cell therapy and neurorehabilitation have led to significant improvements in outcomes for patients but further innovation is still needed. The global Traumatic Brain Injury Therapeutics Market is estimated to be valued at US$ 3.5 Bn in 2024 and is expected to exhibit a CAGR of 34% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing incidence of road injuries and contact sports is the major factor driving the growth of traumatic brain injury therapeutics market. As per CDC estimates, over 2.8 million TBI occur each year in the United States alone. Also growing geriatric population is another important risk factor, with elderly being more susceptible to falls and subsequent head injuries. However, lack of approved therapeutics specifically targeting TBI pathology is a major challenge. While many drugs in preclinical and clinical trials target individual aspects like neuroinflammation, neuronal death, none till date have proven effective clinically. The industry is investing more in development of advanced therapies like neural stem cell therapy and neuroprosthetics to enhance functional recovery in moderate to severe TBI patients.

Porter’s Analysis
Threat of new entrants: The traumatic brain injury therapeutics market size requires significant investment in R&D for drug development. The intellectual property and regulatory barriers make it difficult for new players to enter the market.

Bargaining power of buyers: Individual buyers have little bargaining power due to the severe implications of traumatic brain injuries. However, large hospitals and healthcare providers can negotiate on price and contract terms.

Bargaining power of suppliers: Major suppliers include contract manufacturing organizations and raw material providers. Suppliers have moderate bargaining power due to the availability of substitute suppliers.

Threat of new substitutes: Alternatives for traumatic brain injury treatment include physical therapy, cognitive rehabilitation, and lifestyle changes. However, drug therapy remains the primary treatment option, restricting threats from substitutes.

Competitive rivalry: The market comprises large pharmaceutical companies and small startups. Competition is high based on product innovation, pricing, and portfolio expansion into new indications.

Key Takeaways
The global Traumatic Brain Injury Therapeutics Market is expected to witness high growth over the forecast period of 2024 to 2031.

Regional analysis: North America holds the highest market share due to rising head injuries from road accidents. Europe holds the second largest share with focus on head injury management. The Asia Pacific region is expected to grow at the fastest pace with developing healthcare infrastructure and growing medical tourism industry.

Key players: Key players operating in the Traumatic Brain Injury Therapeutics market are Microsoft, IBM, Dynatrace, Datadog, Splunk, New Relic, GitLab, CircleCI, CloudBees, Snyk, Twistlock, Qualys, Salesforce, SAP, Adobe, Oracle, VMware, Red Hat, and Rancher Labs, Sysdig. Microsoft focuses on cognitive assessment and rehabilitation for TBI patients. IBM uses AI for early diagnosis and treatment monitoring.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraaged AI tools to mine information and compile it